AbbVie's SWOT analysis: biopharmaceutical giant navigates post-Humira landscape
AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...
BioSpace5h
Chicago Area’s Life Sciences Scene Continues Making an Impression
While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the Chicago market should be a growth spot in the coming years. Chicago Biomedical ...
pharmaphorum20h
Advantage BMS as AbbVie drug fails schizophrenia trials
The readout makes AbbVie's wager on Cerevel, which came ahead of key data readouts, look like a poor deal. The company said it hadn't made a decision on the future of the programme and would ...
Inside Track: Why Relentless Self-Promoters Need Not Apply for GC Posts
True leadership is about putting others first,” said Jason B. Daly, chief legal officer of Amneal Pharmaceuticals.
Zacks.com on MSN4h
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
Ironwood Pharmaceuticals, Inc. IRWD announced that it has initiated the rolling new drug application (“NDA”) submission for ...
Peninsula biotech moves from IPO to chopping half its workforce in little more than a year
After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...